VA-REGULA
25.1.2024 08:01:35 CET | Business Wire | Press release
Before adopting an IDV system, it’s imperative to conduct thorough testing, especially for large-scale businesses. However, it is nearly impossible to obtain a reliable set of IDs with real NFC chips (as they contain sensitive personal data) to test-drive the verification process. Besides, it’s not that easy to test both positive and negative verification scenarios without representative ID sampling. Regula’s unique service, Regula NFC TestKit, effectively addresses these issues.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240124863941/en/
An example of a test ID made for Regula NFC TestKit service customers (Photo: Business Wire)
Depending on the particular company’s business needs and market goals, Regula creates a test set of identity documents with NFC chips which are personalized with the data of fictitious identities or those provided by the customer. Apart from the chip, a visual zone and a machine readable zone (MRZ) can also be generated to enable robust cross-checking and system testing. These test IDs are simplified images (with special marks to show that they are not full replicas) of the required pages of the documents the company intends to verify. They are backed up with corresponding templates in a special database version so that the IDV solution can recognize them properly.
By choosing Regula NFC TestKit service, enterprises can benefit from:
- Shorter time to market. Checking and fine-tuning the IDV process with the help of test documents eliminates the necessity of undergoing an early adoption period during which a company could face friction.
- Enhanced IDV solution trial and early problem identification. Regula NFC TestKit service provides the most complete representation of identity documents with multiple data fields. That means any organization can test-drive the complete remote onboarding procedure to address potential issues or vulnerabilities.
- Flexibility and customization. Regula’s service is tailored to the specific needs of any given organization. It is possible to create an NFC-chip-based document sample of any type from any country to test the most likely customer onboarding scenarios.
- Maximum security assurance. Using NFC chips and replicating the data in the MRZ and visual zone ensures that IDV process testing mimics real-life scenarios to get ready to handle customers’ personal data securely.
To enable this service, Regula leverages its unique competencies in forensic examination, as well as IDV software and hardware development. The company personalizes NFC chips with fictitious persons’ data, which is recorded with the help of Regula’s document readers. Importantly, Regula generates all necessary certificate chains for every country in the list, signs the data using these certificates, and provides them to the customer for performing passive authentication. This approach fully imitates the scenario with real NFC chips in real IDs, which allows businesses to take advantage of lifelike document verification when testing their IDV systems.
Regula NFC TestKit is equipped with this functionality thanks to the fact that it is backed by the world’s most comprehensive identity document template database, which is exclusively owned and maintained by Regula. With more than 13,000 templates of IDs from 247 countries and territories, this database makes it possible to imitate nearly any identity document for testing purposes. And thanks to this asset, Regula is able to cover any geography a business may be interested in.
“Businesses currently strive to find suitable solutions to independently test the remote onboarding process of electronic documents, and until now, there have been no offerings on the market to address this gap. With our new service for complete imitation of real IDs, we enable organizations to conduct highly efficient testing to identify and prevent any potential issues prior to the launch of their IDV systems,” says Ihar Kliashchou, Chief Technology Officer at Regula.
Regula NFC TestKit service is provided exclusively for large enterprises that purchase the company’s software solutions. To learn more, contact Regula’s experts.
About Regula
With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed.
Regula was named a Representative Vendor in the Gartner® Market Guide for Identity Verification in 2023.
Learn more at regulaforensics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240124863941/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
